Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
NCT07660094 · LuTK03 Phase 3Recruiting
- Lead sponsor
- Candel Therapeutics, Inc. (Industry)
- Enrollment
- 500 (estimated)
- Start date
- 15 Jun 2026
- Primary completion
- 22 Oct 2031 (estimated)
- Study completion
- 22 Oct 2031
- Last update posted
- 22 Jun 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Aglatimagene Besadenovec Biological
- Valacyclovir Drug
- Pembrolizumab Biological
- Docetaxel Drug
Conditions and primary outcome
- Non-squamous, Non-Small Cell Lung Cancer
Primary outcome
Overall Survival (From date of randomization until date of death from any cause, assessed for a minimum of 24 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07660094.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07660094 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.